Close the sale of the Baltimore-Bayview manufacturing site
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 10 Mar 2025
- Due
- 31 Mar 2025
- Delivered
- 19 Mar 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The sale is expected to close in the first quarter of 2025, subject to the satisfaction of customary closing conditions.”
What we found
Evidence strength A What the grades mean
Emergent BioSolutions completed the sale of its Baltimore-Bayview manufacturing facility to Syngene International on March 19, 2025, which is within the first quarter of 2025.
-
A Emergent BioSolutions Inc. 10-Q filed 2025-05-08
“On March 19, 2025, the Company completed the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International (“Syngene”).” ✓ confirmed on the page
Market reaction: the shares moved +19.3% against the S&P 500 over the three sessions around the disclosure (7 May 2025 to 12 May 2025). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Acquisition close
- Indicative materiality
- High rules
- Action
- Close
- Deliverable
- Baltimore-Bayview manufacturing site
- Where
- Baltimore
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: subject to the satisfaction of customary closing conditions
- Depends on
- Counterparty
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Emergent BioSolutions Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-EBS-002499 · Corrections policy